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Preliminarily, these results indicate community pharma-
cists are having a positive impact on treatment outcomes
and self-reported medication persistence of dyslipidemic
patients. CONCLUSIONS: Working collaboratively with
patients and physicians, pharmacists in this study pro-
vided a comprehensive dyslipidemia management pro-
gram that improved the treatment outcomes for dyslipi-
demic patients. As the debate continues concerning the
prescription versus non-prescription status of “statin”
therapies, studies such as this that indicate monitoring of
lipid lowering therapy can be instituted in varying ambu-
latory sites will provide useful data for professional and
regulatory groups.
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OBJECTIVES: To highlight the impact of post-fracture
treatment costs and time horizon on the cost-effectiveness
of hypothetical interventions. METHODS: A Markov
model was used to simulate the natural history of os-
teoporosis and the clinical, economic and health-related
quality of life impacts of a hypothetical post-menopausal
osteoporosis intervention. The intervention was assumed
to reduce all fractures (50% vertebral and hip; 25% wrist
and other), and cost $650 (US $) annually. The model
tracked the annual incidence of all fractures (vertebral,
hip, wrist, other), as well as mortality due to natural
causes and hip fractures. Age-specific mortality and frac-
ture incidence rates were derived from published US data
sources. Fracture rates were adjusted to reflect a patient
population at increased risk due to low BMD (T-score
2.5) and an existing vertebral fracture. Acute fracture
costs (within year of fracture) and annual fracture costs
in all years subsequent to the hip or vertebral fracture
were taken from the NOF status report (1998). RE-
SULTS: When patients were treated from 70 years of age
for five years and costs collected over a similar time
frame, the cost per QALY gained was estimated as ap-
proximately $20,000. When the treatment length re-
mained 5 years but the time horizon over which costs
were accumulated was increased to 30 years (or until
death), the incremental ratio approached a win-win (re-
duced costs, increased QALYs). Several analyses were
conducted to determine the components contributing to
this trend. CONCLUSIONS: Dramatic change in the
cost-effectiveness of an intervention can be produced by
modifying time horizon. The Canadian and other guide-
lines for economic evaluations recommend a time hori-
zon sufficient to capture all downstream therapy effects.
This work provides an example of the importance of time
horizon selection. In addition, it highlights the need for
accurate long-term costs of hip and vertebral fractures.
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OBJECTIVES: Rheumatoid arthritis and osteoarthritis
are important causes of morbidity in the population. The
objective of this study was to quantify the loss in health
related quality of life due to RA and OA diseases.
METHODS: 127 RA and 167 OA consecutive outpa-
tients were included in the study at 9 sites in the capital
and in the rest of Hungary in 1999. Both patient groups
filled in the EQ-5D questionnaire. In addition, RA pa-
tients filled in the HAQ while OA patients filled in the
WOMAC questionnaires. EQ-5D weighted index values
of the two patient groups were compared to those of the
general Hungarian population. HAQ and WOMAC
scores were correlated to EQ-5D weighted index values.
RESULTS: Five age groups were defined as people be-
tween the age of 35–44, 45–54, 55–64, 65–74, and
75–84. Mean EQ-5D weighted index values were 0.634,
0.517, 0.459, 0.34, and 0.34 among RA patients and
0.688, 0.429, 0.339, 0.415, and 0.359 among OA pa-
tients, respectively. Corresponding EQ-5D weighted in-
dex values are known to be 0.875, 0.813, 0.736, 0.705,
and 0.675 among the general population. Differences be-
tween the general population and the patients groups
were statistically significant (P  0.05). The correlation
coefficient between the EQ-5D weighted index and the
HAQ, WOMAC Pain, WOMAC Stiffness, WOMAC
Physical function scores were 0.552, 0.552, 0.187,
and 0.553, respectively. CONCLUSIONS: Rheumatoid
Arthritis and Osteoarthritis diseases lead to huge losses in
health related quality of life and this should be recog-
nized in global health statistics and in health policy prior-
ity setting.
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